Spondyloarthritis & psoriatic arthritis
Exploring complement biomarkers in suspected axial spondyloarthritis
Authors' conclusion
Serum levels of complement activation, that is, C3dg, and MASP-3 differed significantly between axSpA and cLBP patients after adjustment for CRP.
Study context
- Population
- Cross-sectional OptiRef cohort with suspected axial spondyloarthritis (axSpA): newly diagnosed axSpA and chronic low back pain (cLBP) individualsOptiRef cohort
- Participants
- 515 participants
- Exposure
- Serum lectin pathway proteins in newly diagnosed axSpA vs cLBP
- axSpAn = 151
- cLBPn = 364reference
- Outcome
- Serum lectin pathway proteins (LPPs) (mannan-binding lectin (MBL), CL-L1, M-, H- and L-ficolin, MASP-1, −2, −3, MAp19, MAp44) and C3dg as biomarkers for axSpA
Methodological detailsdiagnostic biomarker study
- Diagnostic biomarker study
Main finding
As reported in the abstract
Serum LPP levels, axSpA vs cLBP
- L-ficolin, MASP-2 and C3dg elevated in axSpA; MASP-3 and CL-L1 decreased
- Difference remained significant for C3dg and MASP-3 after adjustment for C reactive protein (CRP)
- CL-L1, MASP-2, MASP-3 and C3dg predicted axSpA diagnosis in univariate regression; MASP-3 and C3dg remained significant in multivariate logistic regression
Observational data: associations, not effects.
Further findings
Diagnostic potential: Human leukocyte antigen B27 (HLA-B27) combined with L-ficolin, MASP-3 and C3dg
- Increased diagnostic specificity for axSpA, with concomitant loss of sensitivity
Original publication
Exploring complement biomarkers in suspected axial spondyloarthritis. RMD Open. Published 15 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →